HB2810, titled the Family Cord Blood Banking Act, would amend the Internal Revenue Code to treat amounts paid for private umbilical cord blood banking or umbilical cord tissue banking as qualified medical care expenses. In practical terms, the bill would allow taxpayers to include these costs within the category of medical expenses that may be eligible for tax benefits under existing federal tax rules, provided the services are performed by an accredited bank that complies with applicable Public Health Service Act regulations.
The bill applies prospectively to taxable years beginning after December 31, 2024. It does not create a new program or mandate coverage; rather, it changes tax treatment by expanding the definition of medical care expenses in Section 213(d)(1) of the Internal Revenue Code. The measure was introduced in the House and referred to the Committee on Ways and Means, with no recorded votes or committee transcript available in the provided materials.
Impact
The bill would amend federal tax law by adding private umbilical cord blood and cord tissue banking services to the list of expenses treated as medical care under Section 213(d) of the Internal Revenue Code. This could affect taxpayers who pay out of pocket for these services by making them potentially deductible or otherwise eligible for medical-expense-related tax treatment under existing law. The bill also ties eligibility to accredited banks in compliance with Public Health Service Act regulations, which limits the benefit to regulated providers and may influence the market for cord blood banking services.
Sentiment
The available context suggests generally favorable or bipartisan support for the bill’s concept, as indicated by its introduction by Mr. Arrington with co-sponsors Mr. Panetta and Mr. Davis of North Carolina. No committee transcript or vote record is available, so there is no direct evidence of debate, opposition, or amendments in the provided materials. The absence of recorded controversy suggests the measure may be relatively noncontroversial at this stage, though it has only been referred to committee and has not advanced further in the provided record.
Contention
The main policy questions likely concern whether private cord blood and cord tissue banking should be treated as a medical necessity for tax purposes, and whether expanding medical-expense eligibility could create a tax preference for a service that is often elective and preventive rather than immediately therapeutic. Another possible point of contention is the use of federal tax policy to encourage a private-market service, as opposed to broader public banking or other maternal and child health priorities. The bill’s accreditation and compliance requirements may also be relevant to supporters and critics alike, since they narrow eligibility to regulated providers.